Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aerie Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or greater.
Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)
Corrected visual acuity in each eye equivalent to 20/200 or better
Able and willing to give signed informed consent and follow study instructions.
You may not be if
Ophthalmic:
Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.
Intraocular pressure \>36 mmHg
Known hypersensitivity to any component of the formulation, latanoprost, or to topical anesthetics.
Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s)
Refractive surgery in study eye(s)
Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.
Evidence of ocular infection and inflammation
Clinically significant ocular disease, which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe
Central corneal thickness greater then 600 μm
Any abnormality preventing reliable applanation tonometry of either eye
Systemic:
Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.
Clinically significant systemic disease
Participation in any investigational study within 30 days prior to screening
Changes in systemic medication
Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
